An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Janux Therapeutics to Present at Upcoming Investor Conferences in November
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Janux Therapeutics (Nasdaq: JANX) announced participation in two investor conferences. The Piper Sandler 34th Annual Healthcare Conference will be held on November 29, from 8:50am to 9:10am ET in New York, while the 5th Annual Evercore ISI HealthCONx Conference is scheduled for November 30, from 12:35pm to 12:55pm ET as a virtual fireside chat. Janux focuses on developing novel immunotherapies through its TRACTr and TRACIr platforms, targeting prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings. Details of the presentations are as follows:
Piper Sandler 34th Annual Healthcare Conference
Date: Tuesday, November 29 Time: 8:50am to 9:10am Eastern Time Forum: Company Presentation
Location: New York, NY
5th Annual Evercore ISI HealthCONx Conference Dates: Wednesday, November 30 Time: 12:35pm to 12:55pm Eastern Time Forum: Virtual Fireside Chat
About Janux Therapeutics
Janux Therapeutics is an innovative clinical-stage biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations by offering accuracy, stability, activity, modularity, and manufacturability. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Janux is also applying its proprietary technology to develop a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and Cluster of Differentiation 28 (CD28) designed to further enhance the anti-tumor activity of T cells. For more information, please visit www.januxrx.com.
Media:
Jessica Yingling, Ph.D.
Little Dog Communications Inc. jessica@litldog.com
(858) 344-8091
Source: Janux Therapeutics, Inc.
FAQ
When will Janux Therapeutics present at the Piper Sandler Healthcare Conference?
Janux Therapeutics will present at the Piper Sandler 34th Annual Healthcare Conference on November 29, from 8:50am to 9:10am Eastern Time.
What time will Janux Therapeutics participate in the Evercore ISI HealthCONx Conference?
Janux Therapeutics will participate in the Evercore ISI HealthCONx Conference on November 30, from 12:35pm to 12:55pm Eastern Time.
What are the main focuses of Janux Therapeutics' research?
Janux Therapeutics focuses on developing novel immunotherapies through its TRACTr and TRACIr platforms, targeting cancer-related proteins like PSMA, EGFR, and TROP2.
What is the stock symbol for Janux Therapeutics?
The stock symbol for Janux Therapeutics is JANX.
What technology does Janux Therapeutics use for cancer treatment?
Janux Therapeutics utilizes its proprietary TRACTr and TRACIr technologies to develop T cell engagers and immunomodulators for cancer treatment.
